Clinical trial · Observational
SEMA4C as a Relapse Biomarker in Breast Cancer
NCT03663153CI-TRIAL-00054324unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer remains the most common cancer in women worldwide. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The objective of this study is to investigate SEMA4C's potential role as an early relapse biomarker in breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SEMA4C high value follow-up group | Other | — | UNRESOLVED |
| SEMA4C low value follow-up group | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- SEMA4C high value follow-up group
- description
- Postoperative SEMA4C value is higher than 5.00 ng/ml.
- interventionNames
- Other: SEMA4C high value follow-up group
- label
- SEMA4C low value follow-up group
- description
- Postoperative SEMA4C value is lower than 5.00 ng/ml.
- interventionNames
- Other: SEMA4C low value follow-up group
Primary outcomes (1)
- measure
- diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of SEMA4C in predicting recurrence of breast cancer
- timeFrame
- 5 years
- description
- Analyze the sensitivity, specificity, positive predictive value, negative predictive value, accuracy of SEMA4C in predicting recurrence of breast cancer
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Have histologically confirmed new diagnosis of breast cancer according to biopsy or surgery Exclusion Criteria: * Patients who are not mentally capable of giving written informed consent * Serum samples doesn't qualified * Patients who refuse follow-up on their conditions * Patients with prior cancer history * Patients with a diagnosis of other severe acute or chronic medical may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the Investigator, would make the patient inappropriate for enrollment in this study
References
Publications (2)
- BACKGROUNDWei JC, Yang J, Liu D, Wu MF, Qiao L, Wang JN, Ma QF, Zeng Z, Ye SM, Guo ES, Jiang XF, You LY, Chen Y, Zhou L, Huang XY, Zhu T, Meng L, Zhou JF, Feng ZH, Ma D, Gao QL. Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C. Clin Cancer Res. 2017 Jan 1;23(1):214-224. doi: 10.1158/1078-0432.CCR-16-0741. Epub 2016 Jul 8. PMID 27401250
- BACKGROUNDGurrapu S, Pupo E, Franzolin G, Lanzetti L, Tamagnone L. Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. Cell Death Differ. 2018 Jul;25(7):1259-1275. doi: 10.1038/s41418-018-0097-4. Epub 2018 Mar 19. PMID 29555978